Trademark: 87777607
Word
ENGENSIS
Status
Registered
Status Code
700
Status Date
Tuesday, March 12, 2019
Serial Number
87777607
Registration Number
5694789
Registration Date
Tuesday, March 12, 2019
Mark Type
4000
Filing Date
Wednesday, January 31, 2018
Published for Opposition
Tuesday, October 2, 2018

Trademark Owner History
HELIXMITH CO., LTD -
ViroMed Co., Ltd. - Original Registrant

Classifications
5 Chemical reagents for use in veterinary genetic testing; reagents for use in medical genetic testing; diagnostic preparations for medical purposes for detecting mutation in prion genes; preparations for medical purposes for detecting mutation in prion genes; chemical preparations for pharmaceutical purposes, namely, for painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; drugs for medical purposes, namely, prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; medicines for human purposes, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for diagnosis of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; ethical medicinal preparations, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical preparations for use in medical DNA analysis; genetic treatment pharmaceutical preparations
42 Pharmaceutical research and development; pharmaceutical research services; consultancy relating to pharmaceutical research and development; research and development of vaccines and medicines; scientific research in the fields of biomedicine; research and testing services in the fields of bacteriology and virology; drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services

Trademark Events
Mar 12, 2024
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Jun 19, 2019
Automatic Update Of Assignment Of Ownership
May 10, 2019
Review Of Correspondence Complete - Certificate Of Reg Mailed
Mar 12, 2019
Registered-Principal Register
Feb 5, 2019
1(B) Basis Deleted; Proceed To Registration
Dec 21, 2018
Notice Of Allowance Cancelled
Feb 5, 2019
Case Assigned To Intent To Use Paralegal
Dec 21, 2018
Teas Delete 1(B) Basis Received
Nov 27, 2018
Noa E-Mailed - Sou Required From Applicant
Oct 2, 2018
Official Gazette Publication Confirmation E-Mailed
Oct 2, 2018
Published For Opposition
Sep 12, 2018
Notification Of Notice Of Publication E-Mailed
Aug 24, 2018
Approved For Pub - Principal Register
Aug 23, 2018
Teas/Email Correspondence Entered
Aug 23, 2018
Correspondence Received In Law Office
Aug 23, 2018
Teas Response To Office Action Received
May 14, 2018
Notification Of Non-Final Action E-Mailed
May 14, 2018
Non-Final Action E-Mailed
May 14, 2018
Non-Final Action Written
May 14, 2018
Assigned To Examiner
May 1, 2018
Teas/Email Correspondence Entered
May 1, 2018
Correspondence Received In Law Office
May 1, 2018
Assigned To Lie
Apr 24, 2018
Teas Voluntary Amendment Received
Feb 9, 2018
New Application Office Supplied Data Entered
Feb 3, 2018
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24